Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Gore Range Capital is a specialized healthcare investment firm founded in 2015 and headquartered in New York. The firm focuses on building science-led platforms across various sectors, including precision health, regenerative medicine, personalized therapeutics, longevity, and restorative medical sciences. By combining the operational discipline of private equity with the scientific partnership model of venture investing, Gore Range Capital works closely with its portfolio companies to provide strategic, financial, and clinical guidance.
Since its inception, Gore Range Capital has established itself as a key player in the healthcare investment landscape. The firm emphasizes innovations that integrate scientific discovery with clinical and commercial scalability, particularly in skin health, which serves as a biological gateway to overall health and longevity. The firm’s approach is characterized by a commitment to addressing the root causes of aging, chronic disease, and functional decline through next-generation healthcare solutions.
As of now, Gore Range Capital has a diverse portfolio of companies and continues to seek out new investment opportunities that align with its mission. The firm operates primarily in North America and has built a reputation for its deep understanding of the healthcare sector, making it an attractive partner for startups aiming to innovate in this space.
Gore Range Capital invests in companies developing next-generation healthcare solutions that address the root causes of aging, chronic disease, and functional decline. The firm emphasizes innovations that integrate scientific discovery with clinical and commercial scalability. Key sectors of interest include healthcare, biotech, longevity, regenerative medicine, digital health, medical devices, and precision health.
A significant area of focus for Gore Range Capital is skin health, which the firm considers a biological gateway to health and longevity. The firm seeks to support technologies and therapies that begin with clinically accessible biological systems and expand into broader healthcare applications. Gore Range Capital typically invests at various stages, including seed, Series A, Series B, and growth equity, allowing for flexibility in its investment strategy.
Gore Range Capital looks for founders who demonstrate a strong understanding of their market and possess a clear vision for their company's growth. The firm values innovations that can be clinically validated and have the potential for commercial scalability. Additionally, Gore Range Capital prefers to engage in partnerships that allow for close collaboration with portfolio companies, providing them with the necessary resources and guidance to succeed.
Gore Range Capital has built a notable portfolio of companies that exemplify its investment thesis in healthcare innovation. Key portfolio companies include:
These companies reflect Gore Range Capital's commitment to supporting innovative healthcare solutions that address significant medical challenges and improve patient outcomes.
Ethan Rigel - Managing Partner. Ethan has a background in finance and previously served as CFO at LedgerX. He has extensive experience in venture capital and private equity, focusing on healthcare investments.
Ting Pau Oei - Venture Partner. Ting is involved in supporting healthcare and skin-health platforms, leveraging her expertise in the biotech sector.
Humberto Antunes - Partner. Humberto has been instrumental in the firm's partnership with Croma and Waldencast, contributing to the strategic direction of portfolio companies.
Chidi Nwankpa, MD, MBA - Principal. Chidi brings a medical background to the firm, enhancing its understanding of clinical needs and regulatory pathways.
Matt Leavitt, DO, FAAD - Executive Partner. Matt's expertise in dermatology and aesthetics supports the firm's focus on skin health innovations.
John Freidman - Senior Advisor. John provides strategic insights and guidance based on his extensive experience in the healthcare investment space.
Lloyd Appel - Chief Financial Officer. Lloyd oversees the financial operations of the firm, ensuring sound fiscal management.
Darrell Rigel, MD, FAAD - Advisory Board Chair. Darrell leads the scientific advisory board, providing clinical insights and expertise.
April W. Armstrong, MD, FAAD, MPH - Scientific Advisor. April contributes her knowledge in dermatology and public health to the advisory board.
Neal Bhatia, MD, FAAD - Scientific Advisor. Neal offers insights into dermatological therapies and innovations.
Seemal R Desai, MD, FAAD - Scientific Advisor. Seemal provides expertise in skin health and regenerative medicine.
Lawrence Kauvar, PhD - Scientific Advisor. Lawrence brings a research background to the advisory board, focusing on scientific advancements in healthcare.
Richard D. Granstein, MD, FAAD - Scientific Advisor. Richard contributes his clinical expertise in dermatology to the advisory board.
Joel L. Cohen, MD, FAAD - Scientific Advisor. Joel offers insights into aesthetic medicine and dermatological treatments.
Aaron S. Farberg, MD, FAAD - Scientific Advisor. Aaron provides expertise in dermatology and skin health innovations.
Gary Goldenberg, MD, FAAD - Scientific Advisor. Gary contributes his knowledge in dermatology and clinical practice to the advisory board.
To pitch Gore Range Capital, founders should use the contact email info@gorerangecapital.com or visit their website at https://www.gorerangecapital.com/. The firm maintains an open pitch policy and encourages startups to submit their proposals through their online platform. Founders should include a clear overview of their business model, market opportunity, and how their solution aligns with Gore Range Capital's investment focus.
While specific response times are not disclosed, founders can expect a rolling application cycle. It is advisable to follow up if there is no response within a reasonable timeframe. Warm introductions are not explicitly required, but they can enhance the chances of getting noticed.
In July 2025, Gore Range Capital announced the sale of Novaestiq Corp. to Waldencast, marking a significant exit for the firm. This transaction highlights the firm's ability to identify and nurture promising healthcare innovations.
In 2024, Palvella Therapeutics received a grant from the U.S. Food and Drug Administration for its work in orphan products development, showcasing the firm's commitment to supporting companies that address rare diseases.
Additionally, Eirion Therapeutics has been involved in a clinical trial for a potential breakthrough treatment for hair loss, indicating ongoing activity and innovation within Gore Range Capital's portfolio.
What are Gore Range Capital's investment criteria?
Gore Range Capital invests in companies that are developing next-generation healthcare solutions, particularly those addressing aging, chronic disease, and functional decline. The firm focuses on innovations that integrate scientific discovery with clinical and commercial scalability.
How can I pitch to Gore Range Capital?
Founders can pitch to Gore Range Capital by visiting their website and using the contact email info@gorerangecapital.com. The firm maintains an open pitch policy and encourages startups to submit their proposals through their online platform.
What makes Gore Range Capital different from other investors?
Gore Range Capital combines the operational discipline of private equity with the scientific partnership model of venture investing. This unique approach allows them to provide strategic, financial, and clinical guidance to their portfolio companies, enhancing their chances of success.
What is the geographic scope of Gore Range Capital's investments?
The firm primarily operates in North America but is open to global healthcare markets, focusing on innovative healthcare solutions that can scale effectively.
What is the typical check size for investments?
While specific check sizes are not disclosed, Gore Range Capital invests across various stages, including seed, Series A, Series B, and growth equity, indicating a flexible investment approach.
What kind of support can portfolio companies expect?
Gore Range Capital provides strategic, financial, and clinical guidance to its portfolio companies, leveraging its expertise in healthcare science and operational discipline to support their development, regulatory progress, and commercialization.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.